Edwards Lifesciences (EW) Misses Q4 EPS by 4c, Beats on Revenue; Offers Q1 Guidance
Tweet
Share
E-mail
Get Alerts EW Hot Sheet
Price: $90.46 -0.79%
EPS Growth %: +10.4%
Financial Fact:
Diluted (in dollars per share): 0.65
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: +10.4%
Financial Fact:
Diluted (in dollars per share): 0.65
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.58, $0.04 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $1.57 billion versus the consensus estimate of $1.55 billion.
GUIDANCE:
Edwards Lifesciences sees Q1 2026 EPS of $0.70-$0.76, versus the consensus of $0.69. Edwards Lifesciences sees Q1 2026 revenue of $1.55-1.63 billion, versus the consensus of $1.57 billion.
For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
- Goldman Sachs Upgrades Lumo Kodit Oyj (LUMO:FH) to Buy
- AeroVironment (AVAV) Tops Q4 EPS by 36c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
